infliximab

Infliximab is a chimeric monoclonal antibody that targets and neutralizes tumor necrosis factor-alpha (TNF-alpha), a pro-inflammatory cytokine involved in the pathogenesis of several autoimmune diseases. By binding to TNF-alpha, infliximab inhibits its activity, thereby reducing inflammation and modulating immune responses. It is primarily used to treat moderate-to-severe Crohn's disease, ulcerative colitis, rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis, ankylosing spondylitis, and chronic severe plaque psoriasis in adults and children who have not responded adequately to other therapies. Infliximab was originally developed by Centocor (now part of Johnson & Johnson) and first approved under the brand name Remicade in 1998[1][2][5]. Multiple biosimilars are now available.

Brand names

RemicadeAvsolaInflectraRenflexisIxifiZymfentra

Other names

unbranded infliximab